Funding Support and Author Disclosures Supported by national funds through FCT (Fundação para a Ciência e Tecnologia), I.P., within the scope of the Cardiovascular R&D Center (UIDB/00051/2020 and UIDP/00051/2020) and RISE (LA/P/0053/2020). Dr Neves has received consulting and speaker fees from AstraZeneca, BIAL, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; and has received speaker fees from Merck. Dr Zannad has received personal fees from 89bio, Applied Therapeutics, Bayer, Biopeutics, Boehringer, BMS, CVRx, Cardior, Cambrian, Cereno pharmaceutical, Cellprothera, CEVA, Merck, Novartis, Novo Nordisk, Otsuka, Owkin, and Servier; has stock options at G3Pharmaceutical; has equities at Cereno Pharmaceutical, Cardiorenal, and Eshmoun Clinical research; and is founder of Cardiovascular Clinical Trialists (CVCT). Dr Butler has received consulting fees from Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Roche, Sequana, SQ Innovation, and Vifor. Dr Packer has received consulting fees from 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Lilly, Medtronic, Moderna, Novartis, Pharmacocosmos, Reata, Relypsa, and Salamandra. Dr Ferreir has received consulting fees from Boehringer Ingelheim and AstraZeneca; and has received research support from Novartis, Boehringer Ingelheim, AstraZeneca, and Bayer through his institution.